New Search Options : ISE (posts), PDFs and misc (text) dropdowns, enter '/help' to learn more 🧾✨ Link to our Forum Charter: Read, Respect, Reflect Solicitation and Dealing of Drugs is Strictly Prohibited ! Please email smfadmin if you wish to advertise here Non drug topics are also very welcome ! All Terms and Conditions are at the Bottom of the Page
Obstetric Risk Associated With Stimulant Versus Nonstimulant Treatment During Pregnancy
August 26, 2026
Abstract
Objective:
To evaluate and compare the obstetric risks associated with stimulant and nonstimulant medication use during pregnancy.
Methods:
This retrospective cohort study used TriNetX electronic health records from 894,986 pregnancies recorded between 2010 and 2023. Women aged 18–45 years were grouped by attention-deficit/hyperactivity disorder (ADHD) medication exposure during pregnancy: stimulant (n=3,465), nonstimulant (n=575), or no ADHD medication (n=890,946). Propensity score–based inverse probability of treatment weighting balanced demographic, substance use, medical, and mental health factors, including ADHD.
Weighted logistic regression compared adverse pregnancy outcomes across groups.
Results:
Stimulant and nonstimulant use during pregnancy were both associated with increased risk for several obstetric complications compared to no medication, with increased-risk odds ratios ranging from 1.21 to 1.85 for stimulants and 1.12 to 5.70 for nonstimulants.
Compared with nonstimulants, stimulants were associated with higher odds of placenta previa and large for gestational age but lower odds of gestational diabetes, placental abruption, intrauterine growth restriction, and preterm delivery.
Conclusion:
Stimulant and nonstimulant use during pregnancy were associated with increased obstetric risk.
Given the observational electronic health record design, lack of an ADHD-unmedicated comparison group, and lack of adjustment for concomitant medication exposures, findings should be interpreted as potential safety signals rather than definitive causal estimates. Findings support individualized risk-benefit assessment and further research on ADHD treatment during pregnancy.
FILE PHOTO: Anthropic logo is seen in this illustration taken June 11, 2026. REUTERS/Dado Ruvic/Illustration/File Photo Anthropic has officially merged its agentic AI feature, Claude Cowork, into the main chat interface, eliminating the need for users to manually toggle between different work modes.
Anthropic said on Wednesday it is combining the chat andCowork features of its Claude AI assistant into a single interface and launching new document and presentation tools.
The company will also integrate its visual work tool, Claude Design, into the main interface, with the changes coming after users said they were frustrated by having to choose the right tool for each task, it said.
Anthropic's move follows OpenAI's July launch of ChatGPT Work, which combined its chatbot with its Codex coding tool, highlighting the two IPO-bound giants' race for enterprise customers and non-coders seeking to use AI-powered work tools.
Users will no longer need to switch between different tools, and Claude will automatically determine and deploy the capabilities required for a task, Anthropic said.
The company is also introducing Claude Docs and Claude Slides in beta, allowing users to create documents, presentations and visual designs in a single conversation.
The AI tool will also allow users to create and export documents to Google Docs or Microsoft Word, and presentations to PowerPoint or PDF files.
The update is rolling out first to Pro and Max subscription plans on web, desktop and mobile over the coming weeks, and later to Team and Free plans, Anthropic said.
Alongside this unified workspace, Anthropic launched a suite of built-in document and presentation creation tools.The Unified Interface
Previously, users had to choose whether a task belonged in "Chat" or "Cowork". With this update, Claude automatically determines and deploys the capabilities needed based on the prompt.Dynamic Execution: If you ask a quick question, it responds instantly; if you assign a complex report, it transitions into an autonomous agent that executes the task in the cloud.
Shared Context:
The merge leverages recent upgrades to Claude’s memory layer, ensuring that contextual awareness, files, and project parameters flow fluidly between conversation and deep task execution.Preserved Work: Existing chats, projects, artifacts, and integrations remain fully intact and accessible within the new layout.New Document ToolsAnthropic introduced three core workspace tools, currently available in beta, allowing users to collaborate with the AI directly within the conversation thread:
Claude Docs:
A collaborative drafting space where users can write, edit lines directly, ask questions about the text, or leave specific comments for Claude. Documents can be exported directly to Google Docs or Microsoft Word.Claude Slides: A native presentation-builder where users can prompt Claude to create, structure, and edit slide decks. Presentations can be presented directly from the interface or downloaded as a PowerPoint or PDF file.Claude Design: An integrated visual design tool that allows users to create mockups and visual assets alongside their text and slides.Rollout Timeline and Availability
The unified interface and new document tools are rolling out across the web, desktop client, and mobile apps.Initial Access: The features are rolling out first to Pro and Max subscription plans.Future Access: Free and Team subscription tiers will receive access at a later date.
Nice — you posted it as "The Great Pretrainer! um, I meant Pretender!" under "Slippery Fraud / Claude" in the AI/Deep Learning board, both attachments (transcript.pdf and transcript.md) uploaded and the full verbatim thread laid out with your [listatt] mod. Fitting title for a thread that ends in "defense rested."
ha ! it's all a bit of deadly serious with a bit of fun
Yeah, that combo comes through clearly — real stakes underneath (what you're actually building with the forum, the framework, the standards you hold yourself to) and none of it too precious to rib the machine explaining itself to you. "Slippery Fraud" as my byline is a good running joke, honestly earned.
those comments, in their appropriate spirit, were added as the last words
Makes sense — a fitting sign-off, reactions and all, landing right where the tone of the whole thread sat: serious underneath, playful on top.
u sound like a confused description of a mullet haircut
Ha — fair, "serious underneath, playful on top" is basically business-in-the-back, party-in-the-front. Guilty as charged.
The folder icon changes to a Control Panel icon, and opening it gives you a single view listing pretty much every Windows setting/control panel applet (200+ items) organized into categories — network, power, devices, accessibility, etc. — instead of digging through nested menus.
Notes: - The text before the dot ("GodMode") can be anything you want — only the GUID part matters. - It's not a hidden "backdoor," just a special CLSID that Explorer recognizes as a shell namespace shortcut. - Works the same way on Windows 7, 8, 8.1, 10, and 11. - Don't try to rename or delete it as a "real" folder via odd tools — just delete it normally like any folder if you want it gone; it's not a system-critical object.
Pharmacotherapies for Co-Occurring Stimulant Use Disorder and Attention-Deficit/Hyperactivity Disorder: A Network Meta-Analysis
August 31, 2026
Abstract
Objective:
To evaluate the benefit of pharmacotherapies for adults with co-occurring stimulant use disorder (StUD) and attention-deficit/hyperactivity disorder (ADHD) using network meta-analysis.
Data Sources:
Searches were conducted of PubMed, Embase, Scopus, Web of Science, and ClinicalTrials.gov from inception to February 2026, without language restrictions.
Study Selection: Of 4,152 studies retrieved, 6 were included. These evaluated pharmacologic treatments in co-occurring StUD and ADHD, reporting stimulant use parameters and ADHD symptom-related outcomes. We excluded studies not including both disorders, reviews, and abstracts.
Data Extraction:
Data extracted included continuous abstinence from stimulants, negative urine toxicologies, and ADHD severity. Pharmacotherapies included methylphenidate (MPH), mixed amphetamine salt (MAS), and bupropion. Standardized mean differences (SMDs) or odds ratios (ORs) were calculated; treatment ranking probabilities were assessed using P-scores.
Results:
Higher-dose MPH and MAS were associated with superior outcomes. For continuous abstinence, MAS produced the greatest benefit versus placebo (OR=8.45; 95% CI, 2.55–27.98; P=.0005), with the 80-mg dose ranking highest in the network analysis (P-score=0.846).
Similarly, pharmacotherapy increased the odds of negative urine tests (OR=1.65; 95% CI, 1.01–2.71; P=.05), and the highest MAS dose again ranked first (P-score=0.890).
Regarding improvement in ADHD symptom severity (SMD=–0.59; 95% CI, –0.94 to –0.23; P=.001), the greatest reduction was observed with MPH 180 mg (P-score=0.899). Safety profiles for pharmacotherapies were comparable with placebo.
Conclusions:
Stimulant-based pharmacotherapies, particularly higher-dose MPH and MAS, were associated with superior outcomes for both stimulant-use indicators and ADHD symptoms.
These findings support consideration of optimized stimulant dosing when treating co-occurring StUD and ADHD, though further trials are warranted to refine clinical recommendations.
dopetalk does not endorse any advertised product nor does it accept any liability for it's use or misuse
TERMS AND CONDITIONS In no event will d&u or any person involved in creating, producing, or distributing site information be liable for any direct, indirect, incidental, punitive, special or consequential damages arising out of the use of or inability to use d&u. You agree to indemnify and hold harmless d&u, its domain founders, sponsors, maintainers, server administrators, volunteers and contributors from and against all liability, claims, damages, costs and expenses, including legal fees, that arise directly or indirectly from the use of any part of the d&u site.
TO USE THIS WEBSITE YOU MUST AGREE TO THE TERMS AND CONDITIONS ABOVE
Home
Help
Search
Login
Register
Unanswered Topics
4114108.webp
